Search Results

Xeris Pharmaceuticals, Inc. (Nasdaq: XERS), a specialty pharmaceutical company leveraging its novel formulation technology platforms to develop and commercialize ready-to-use injectable and infusible drug formulations, today announced that it has entered into an exclusive distribution agreement with Megapharm Ltd.

Aeterna Zentaris Inc. (NASDAQ: AEZS) (TSX: AEZS) ( the “Company”), a specialty biopharmaceutical company commercializing and developing therapeutics and diagnostic tests, today announced that it has entered into an exclusive distribution and related quality agreement (the “Agreement”) with Megapharm Ltd. (“Megapharm”), a leading Israel-based biopharmaceutical company, for the commercialization in Israel and the Palestinian Authority of m

Foresee and Megapharm announced today that they have entered into an exclusive license and distribution agreement for the commercialisation in Israel and the Palestinian Authority of Foresee’s FP-001 program.

PharmaMar has announced today a commercialization and distribution license agreement with Megapharm for the marine-derived anticancer drug Aplidin in Israel and the territory known as the Palestinian Authority.

PharmaMar shall receive an upfront payment and is eligible for additional remunerations, including regulatory milestone payments.